| HTGC |
Hercules Capital, Inc. |
72%
|
e cash, cash equivalents, and short-term marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements to the end of 2027. We expect to incur notable ex… |
| HTGC |
Hercules Capital, Inc. |
72%
|
Reciprocal relationship from HTGC graph: Reciprocal relationship from MLTX graph: e cash, cash equivalents, and short-term marketable securities will be sufficient to fund our operating expenses and … |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from NVSE… |
| NVSEF |
Novartis AG |
72%
|
LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we obtain final trial results and know whet… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from ORAN… |
| ORANY |
ORANY |
72%
|
ct trade secrets. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could … |
| ORKA |
Oruka Therapeutics, Inc. |
72%
|
Reciprocal relationship from ORKA graph: ant to license agreements with Paragon. If the patent applications mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those… |
| ORKA |
Oruka Therapeutics, Inc. |
72%
|
LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we obtain final trial results and know whet… |
| PTGX |
Protagonist Therapeutics, Inc. |
72%
|
Reciprocal relationship from PTGX graph: Reciprocal relationship from MLTX graph: LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activi… |
| PTGX |
Protagonist Therapeutics, Inc. |
72%
|
LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we obtain final trial results and know whet… |
| SCNI |
Scinai Immunotherapeutics Ltd. |
72%
|
LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we obtain final trial results and know whet… |
| SCNI |
Scinai Immunotherapeutics Ltd. |
72%
|
Reciprocal relationship from SCNI graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from SCNI graph: Reciprocal relationship from MLTX graph: LK through Phase 3 development and … |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MLTX graph: LK through Phase 3 development an… |
| SNYNF |
Sanofi |
72%
|
LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we obtain final trial results and know whet… |
| CHE-433-093-536-MOONLAKE-IMMUNOTHERAPEUTICS-LTD |
CHE-433-093-536-MOONLAKE-IMMUNOTHERAPEUTICS-LTD |
62%
|
(the “Business Combination Agreement”), by and among Helix, MoonLake AG, the existing equityholders of MoonLake AG set forth on the signature pages to the Business Combination Agreement and the equit… |
| CO-ZURA-BIO-LTD |
CO-ZURA-BIO-LTD |
62%
|
LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we obtain final trial results and know whet… |
| EQUITY-MOONLAKE-AG |
EQUITY-MOONLAKE-AG |
62%
|
ts and liabilities in accordance with ASC 715, Compensation – Retirement Benefits , which requires the recognition of the funded status of pension plans in the Company’s consolidated balance sheet. T… |
| HELIX-ACQUISITION-CORPORATION |
HELIX-ACQUISITION-CORPORATION |
62%
|
(the “Business Combination Agreement”), by and among Helix, MoonLake AG, the existing equityholders of MoonLake AG set forth on the signature pages to the Business Combination Agreement and the equit… |
| HELIX-HOLDINGS-LLC |
HELIX-HOLDINGS-LLC |
62%
|
(the “Business Combination Agreement”), by and among Helix, MoonLake AG, the existing equityholders of MoonLake AG set forth on the signature pages to the Business Combination Agreement and the equit… |
| HELIX-MOONLAKE-AG |
HELIX-MOONLAKE-AG |
62%
|
(the “Business Combination Agreement”), by and among Helix, MoonLake AG, the existing equityholders of MoonLake AG set forth on the signature pages to the Business Combination Agreement and the equit… |
| KYMERA-THERAPEUTICS-INC |
KYMERA-THERAPEUTICS-INC |
62%
|
LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we obtain final trial results and know whet… |
| MOONLAKE-AG |
MOONLAKE-AG |
62%
|
o generate revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of SLK in one or more indications, which we expect to take a number of … |
| MOONLAKE-IMMUNOTHERAPEUTICS-US-INC |
MOONLAKE-IMMUNOTHERAPEUTICS-US-INC |
62%
|
t and license under RCT’s patents and know-how related to a manufacturing process using an underlying yeast strain, Pichia pastoris, to develop, manufacture, use, sell, offer for sale, and import and… |
